Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 13 studies | 33% ± 15% | |
type I pneumocyte | 8 studies | 21% ± 5% | |
plasmablast | 7 studies | 46% ± 18% | |
epithelial cell | 7 studies | 29% ± 15% | |
abnormal cell | 5 studies | 18% ± 2% | |
endothelial cell | 4 studies | 21% ± 4% | |
goblet cell | 4 studies | 22% ± 2% | |
ciliated cell | 3 studies | 33% ± 1% | |
enteroendocrine cell | 3 studies | 21% ± 4% | |
basal cell | 3 studies | 26% ± 11% | |
hepatocyte | 3 studies | 35% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4074.18 | 1445 / 1445 | 100% | 65.69 | 183 / 183 |
lung | 100% | 6691.86 | 578 / 578 | 100% | 124.25 | 1155 / 1155 |
ovary | 100% | 2989.12 | 180 / 180 | 100% | 63.10 | 430 / 430 |
pancreas | 100% | 4671.38 | 328 / 328 | 100% | 68.51 | 178 / 178 |
stomach | 100% | 6041.77 | 359 / 359 | 100% | 65.50 | 286 / 286 |
skin | 100% | 5075.68 | 1808 / 1809 | 100% | 80.47 | 472 / 472 |
prostate | 100% | 4258.15 | 245 / 245 | 100% | 70.22 | 501 / 502 |
uterus | 100% | 3850.76 | 170 / 170 | 100% | 83.17 | 458 / 459 |
liver | 100% | 7838.49 | 226 / 226 | 100% | 60.67 | 405 / 406 |
thymus | 100% | 6678.86 | 653 / 653 | 100% | 90.87 | 603 / 605 |
intestine | 100% | 4889.14 | 966 / 966 | 100% | 72.12 | 525 / 527 |
breast | 100% | 4687.46 | 459 / 459 | 100% | 76.33 | 1113 / 1118 |
kidney | 100% | 5865.03 | 89 / 89 | 99% | 80.86 | 896 / 901 |
bladder | 100% | 4419.62 | 21 / 21 | 99% | 82.83 | 501 / 504 |
brain | 99% | 2513.84 | 2614 / 2642 | 100% | 41.92 | 704 / 705 |
adrenal gland | 100% | 4251.36 | 258 / 258 | 97% | 48.19 | 224 / 230 |
adipose | 100% | 4720.09 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 53.89 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 113.52 | 29 / 29 |
spleen | 100% | 7140.19 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 69.20 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 58.06 | 1 / 1 |
blood vessel | 100% | 4931.89 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 2552.20 | 849 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 1716.52 | 780 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 2879.32 | 887 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_0017121 | Biological process | plasma membrane phospholipid scrambling |
GO_0016020 | Cellular component | membrane |
GO_0012505 | Cellular component | endomembrane system |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0017128 | Molecular function | phospholipid scramblase activity |
Gene name | CLPTM1L |
Protein name | Lipid scramblase CLPTM1L (Cisplatin resistance-related protein 9) (CRR9p) (Cleft lip and palate transmembrane protein 1-like protein) (CLPTM1-like protein) Lipid scramblase CLPTM1L (Cisplatin resistance-related protein 9) (Cleft lip and palate transmembrane protein 1-like protein) |
Synonyms | hCG_1810932 CRR9 |
Description | FUNCTION: Scramblase that mediates the translocation of glucosaminylphosphatidylinositol (alpha-D-GlcN-(1-6)-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol, GlcN-PI) across the endoplasmic reticulum (ER) membrane, from the cytosolic leaflet to the luminal leaflet of the ER membrane, where it participates in the biosynthesis of glycosylphosphatidylinositol (GPI) . GPI is a lipid glycoconjugate involved in post-translational modification of proteins . Can also translocate 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) (phosphatidylinositol or PI), as well as several other phospholipids (1,2-diacyl-sn-glycero-3-phosphocholine, 1,2-diacyl-sn-glycero-3-phosphoethanolamine), and N-acetylglucosaminylphosphatidylinositol (GlcNAc-PI) in vitro . . |
Accessions | G5E9Z2 ENST00000630539.1 ENST00000620010.3 [Q96KA5-1] Q96KA5 ENST00000320895.10 [Q96KA5-1] ENST00000507807.3 ENST00000627897.1 |